The authors summarize the current regulatory expectations regarding the number of PPQ batches required and provide potential approaches that can be used to determine and justify the number of PPQ batches.
Richard A. Lewis
Advertisement
Richard A. Lewis is statistics lead, GMS TEC Shared Services, at GlaxoSmithKline.
Articles by Richard A. Lewis
Advertisement
Latest Updated Articles
Stage 2 Process Validation: Regulatory Expectations and Approaches to Determine and Justify the Number of PPQ BatchesPublished: July 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Executive Summary: Charge Detection Mass Spectrometry (CDMS): From Complexity to Clarity – A New Era in Biomolecular Analysis
5
